Cantor Fitzgerald initiated coverage of Scholar Rock (SRRK) with an Overweight rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- JPMorgan adds Scholar Rock to Focus List, ‘Positive Catalyst Watch’
- GMS jumps after report of competing suitors, Couchbase gets bought: Morning Buzz
- Buy Rating for Scholar Rock Holding: Promising Clinical Advancements and Strategic Focus Highlighted by Phase 2 EMBRAZE Trial Results
- Strategic Focus on Neuromuscular Treatments and Promising Study Results Justify Buy Rating for Scholar Rock
- Scholar Rock’s Strategic Shift and Promising Advancements Drive Buy Rating